Literature DB >> 10887113

Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions.

T Chavakis1, S M Kanse, F Lupu, H P Hammes, W Müller-Esterl, R A Pixley, R W Colman, K T Preissner.   

Abstract

Proteolytic cleavage of single-chain high molecular weight kininogen (HK) by kallikrein releases the short-lived vasodilator bradykinin and leaves behind 2-chain high molecular weight kininogen (HKa) that has been previously reported to exert antiadhesive properties as well as to bind to the urokinase receptor (uPAR) on endothelial cells. In this study we defined the molecular mechanisms for the antiadhesive effects of HKa related to disruption of integrin- and uPAR-mediated cellular interactions. Vitronectin (VN) but not fibrinogen or fibronectin-dependent alphavbeta(3) integrin-mediated adhesion of endothelial cells was blocked by HKa or its isolated domain 5. In a purified system, HKa but not HK competed for the interaction of VN with alphavbeta(3) integrin, because HKa and the isolated domain 5 but not HK bound to both multimeric and native VN in a Zn(2+)-dependent manner. The interaction between HKa or domain 5 with VN was prevented by heparin, plasminogen activator inhibitor-1, and a recombinant glutathione-S-transferase (GST)-fusion peptide GST-VN (1-77) consisting of the amino terminal portion of VN (amino acids 1-77), but not by a cyclic arginyl-glycyl-aspartyl peptide, indicating that HKa interacts with the amino terminal portion of VN ("somatomedin B region"). Furthermore, we have confirmed that HKa but not HK bound to uPAR and to the truncated 2-domain form of uPAR lacking domain 1 in a Zn(2+)-dependent manner. Through these interactions, HKa or its recombinant His-Gly-Lys-rich domain 5 completely inhibited the uPAR-dependent adhesion of myelomonocytic U937 cells and uPAR-transfected BAF-3 cells to VN and thereby promoted cell detachment. By immunogold electron microscopy, both VN and HK/HKa were found to be colocalized in sections from human atherosclerotic coronary artery, indicating that the described interactions are likely to take place in vivo. Taken together, HK and HKa inhibit different VN-responsive adhesion receptor systems and may thereby influence endothelial cell- or leukocyte-related interactions in the vasculature, particularly under inflammatory conditions. (Blood. 2000;96:514-522)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10887113

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin.

Authors:  Jing-Chuan Zhang; Fernando Donate; Xiaoping Qi; Nicholas P Ziats; Jose C Juarez; Andrew P Mazar; Yuan-Ping Pang; Keith R McCrae
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-26       Impact factor: 11.205

2.  The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms.

Authors:  Athanasios N Athanasopoulos; Matina Economopoulou; Valeria V Orlova; Astrid Sobke; Darius Schneider; Holger Weber; Hellmut G Augustin; Sabine A Eming; Uwe Schubert; Thomas Linn; Peter P Nawroth; Muzaffar Hussain; Hans-Peter Hammes; Mathias Herrmann; Klaus T Preissner; Triantafyllos Chavakis
Journal:  Blood       Date:  2005-11-29       Impact factor: 22.113

3.  Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species.

Authors:  Danyu Sun; Keith R McCrae
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

4.  Novel role for p56/Lck in regulation of endothelial cell survival and angiogenesis.

Authors:  Venkaiah Betapudi; Meenal Shukla; Ravi Alluri; Sergei Merkulov; Keith R McCrae
Journal:  FASEB J       Date:  2016-07-11       Impact factor: 5.191

5.  Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.

Authors:  Fang Wang; Jing Li; Anthony L Sinn; W Eric Knabe; May Khanna; Inha Jo; Jayne M Silver; Kyungsoo Oh; Liwei Li; George E Sandusky; George W Sledge; Harikrishna Nakshatri; David R Jones; Karen E Pollok; Samy O Meroueh
Journal:  J Med Chem       Date:  2011-10-04       Impact factor: 7.446

Review 6.  Interactions of integrins with their partner proteins in leukocyte membranes.

Authors:  Howard R Petty; Randall G Worth; Robert F Todd
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Inhibition of pathologic retinal neovascularization by alpha-defensins.

Authors:  Matina Economopoulou; Khalil Bdeir; Douglas B Cines; Franz Fogt; Yasmina Bdeir; Jacek Lubkowski; Wuyuan Lu; Klaus T Preissner; Hans-Peter Hammes; Triantafyllos Chavakis
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

8.  Inhibition of breast cancer cell adhesion and bone metastasis by the extracellular adherence protein of Staphylococcus aureus.

Authors:  Darius Schneider; Lucy Liaw; Carolin Daniel; Athanasios N Athanasopoulos; Mathias Herrmann; Klaus T Preissner; Peter P Nawroth; Triantafyllos Chavakis
Journal:  Biochem Biophys Res Commun       Date:  2007-04-02       Impact factor: 3.575

9.  Saccharomyces boulardii improves intestinal epithelial cell restitution by inhibiting αvβ5 integrin activation state.

Authors:  Alexandra Canonici; Emilie Pellegrino; Carole Siret; Chloé Terciolo; Dorota Czerucka; Sonia Bastonero; Jacques Marvaldi; Dominique Lombardo; Véronique Rigot; Frédéric André
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

10.  The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1.

Authors:  Sentot Santoso; Ulrich J H Sachs; Hartmut Kroll; Monica Linder; Andreas Ruf; Klaus T Preissner; Triantafyllos Chavakis
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.